{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:36:36Z","timestamp":1762497396836,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":104,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.4158\/accr-2020-0216","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:13:28Z","timestamp":1600712008000},"page":"e265-e268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Budesonide-Induced Hyperosmolar Hyperglycemic State Following Transjugular Intrahepatic Portosystemic Shunt"],"prefix":"10.1016","volume":"6","author":[{"given":"Thejus","family":"Jayakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Goodnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Hardman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/ACCR-2020-0216_bb0010","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200262150-00015","article-title":"Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn\u2019s disease in adults","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"10.4158\/ACCR-2020-0216_bb0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1358\/dot.2008.44.11.1297916","article-title":"Oral formulations of budesonide: a novel treatment for inflammatory bowel disease","volume":"44","author":"Svoboda","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.4158\/ACCR-2020-0216_bb0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","article-title":"Oral budesonide for maintenance of remission of Crohn\u2019s disease: a pooled safety analysis","volume":"29","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.4158\/ACCR-2020-0216_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"10.4158\/ACCR-2020-0216_bb0030","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn\u2019s disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.4158\/ACCR-2020-0216_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn\u2019s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.4158\/ACCR-2020-0216_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1021900115403","article-title":"Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn\u2019s disease: results of an open, prospective, multicenter trial","volume":"48","author":"Andus","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.4158\/ACCR-2020-0216_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.2005.02517.x","article-title":"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation","volume":"61","author":"Brunner","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.4158\/ACCR-2020-0216_bb0050","first-page":"803","article-title":"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn\u2019s disease","volume":"43","author":"Edsb\u00e4cker","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.4158\/ACCR-2020-0216_bb0055","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1365-2036.2007.03306.x","article-title":"Oral budesonide in the treatment of chronic refractory pouchitis","volume":"25","author":"Gionchetti","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.4158\/ACCR-2020-0216_bb0060","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.4158\/ACCR-2020-0216_bb0065","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.17554\/j.issn.2224-3992.2018.07.750","article-title":"Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis","volume":"7","author":"Reed","year":"2018","journal-title":"HSOA J Gastroenterol Hepatol Res"},{"key":"10.4158\/ACCR-2020-0216_bb0070","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.4158\/ACCR-2020-0216_bb0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1572-0241.1998.270_1.x","article-title":"Oral budesonide for lymphocytic colitis","volume":"93","author":"Van Gossum","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.4158\/ACCR-2020-0216_bb0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12876-014-0197-7","article-title":"Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)","volume":"14","author":"Schmelz","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.4158\/ACCR-2020-0216_bb0085","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/moe.2003.23","article-title":"Budesonide: a novel treatment for oral chronic graft versus host disease","volume":"95","author":"Elad","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.4158\/ACCR-2020-0216_bb0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijpharm.2007.02.015","article-title":"Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon","volume":"338","author":"Krishnamachari","year":"2007","journal-title":"Int J Pharm"},{"key":"10.4158\/ACCR-2020-0216_bb0095","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/jgh.14151","article-title":"Oral budesonide in gastrointestinal and liver disease: a practical guide for the clinician","volume":"33","author":"Miehlke","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.4158\/ACCR-2020-0216_bb0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000484047","article-title":"Efficacy and safety of oral budesonide in patients with active Crohn\u2019s disease in Japan: a multicenter, double-blind, randomized, parallel-group phase 3 study","volume":"2","author":"Yokoyama","year":"2018","journal-title":"Inflamm Intest Dis"},{"key":"10.4158\/ACCR-2020-0216_bb0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MPG.0000000000000848","article-title":"Adrenal suppression in children treated with oral viscous budesonide for eosinophilic esophagitis","volume":"61","author":"Harel","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.4158\/ACCR-2020-0216_bb0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jceh.2016.05.006","article-title":"Iatrogenic Cushing syndrome from interaction between ritonavir and oral budesonide during direct acting antiviral hepatitis C therapy","volume":"6","author":"Yeoh","year":"2016","journal-title":"J Clin Exp Hepatol"},{"key":"10.4158\/ACCR-2020-0216_bb0115","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/jcpt.12312","article-title":"Iatrogenic Cushing\u2019s syndrome related to the interaction between oral budesonide with fluvoxamine: a case report","volume":"40","author":"Martin","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.4158\/ACCR-2020-0216_bb0120","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/bmt.2012.17","article-title":"Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles","volume":"47","author":"El Fakih","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.4158\/ACCR-2020-0216_bb0125","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cgh.2017.11.003","article-title":"Budesonide in autoimmune hepatitis: the right drug at the right time for the right patient","volume":"16","author":"Manns","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.4158\/ACCR-2020-0216_bb0130","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3748\/wjg.v9.i12.2681","article-title":"Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC","volume":"9","author":"Geier","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.4158\/ACCR-2020-0216_bb0135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.23383","article-title":"The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009","volume":"51","author":"Boyer","year":"2010","journal-title":"Hepatology"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520306234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520306234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:31:47Z","timestamp":1762497107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060520306234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2376060520306234"],"URL":"https:\/\/doi.org\/10.4158\/accr-2020-0216","relation":{},"ISSN":["2376-0605"],"issn-type":[{"type":"print","value":"2376-0605"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budesonide-Induced Hyperosmolar Hyperglycemic State Following Transjugular Intrahepatic Portosystemic Shunt","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/ACCR-2020-0216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}